Stephen Willey joined the Stifel Nicolaus Research Team in connection with Stifel's acquisition of Thomas Weisel Partners LLC in July of 2010. Willey is a Director and follows the Biotechnology industry. Previously, he was a research scientist with ImClone Systems, where he worked in oncology drug discovery and pre-clinical drug development. Before that, Willey was a research associate at Mount Sinai School of Medicine, where he worked in both oncology and stem cell biology. He received a Bachelor's of Science degree from the University of New Hampshire, an Master's degree from the University of Rhode Island, and an Masters of Business Administration from New York University.
"OGXI's economics are likely to emerge as meaningful upside in FY13."
Stephen Willey, Stifel